Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

Business Wire January 28, 2019

Oragenics Inc. to Present at NobleCon15 on January 28, 2019

Business Wire January 25, 2019

Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies

PR Newswire December 6, 2018

Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives

Business Wire November 27, 2018

Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event

Accesswire November 26, 2018

Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

Business Wire November 15, 2018

Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

Business Wire November 14, 2018

Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

Business Wire October 17, 2018

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire October 4, 2018

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

PR Newswire October 3, 2018

Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

Accesswire March 6, 2018

Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement

Business Wire July 26, 2017

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard

Business Wire June 9, 2017

Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference

Business Wire June 6, 2017

CORRECTION FROM SOURCE: Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan

Accesswire May 11, 2017

Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan

Accesswire May 11, 2017

Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results

PR Newswire March 1, 2017

Oragenics Shareholder Update

Business Wire January 4, 2017

Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development

Business Wire December 15, 2016

U.S. FDA Grants Fast Track Designation for the Development of Oragenics’ AG013 for Oral Mucositis

Business Wire November 21, 2016